Papers
12
Total Citations
187
H-Index
8
About
Sheng-Chun Hung is a leading urologic surgeon and researcher whose work bridges the frontiers of prostate cancer genomics and robotic surgical innovation. His research is anchored in two complementary domains: investigating the genetic underpinnings of prostate cancer susceptibility and progression, and refining surgical techniques to improve patient quality of life. Hung’s landmark study on Retzius-sparing robotic-assisted radical prostatectomy (RARP), cited 74 times, demonstrated that this approach significantly reduces bladder neck descent and dramatically improves early continence outcomes, offering a transformative benefit for patients. He has also made pivotal contributions to cancer genomics, identifying how polymorphisms in long noncoding RNAs like GAS5 and MALAT1 influence prostate cancer risk and lymph node metastasis—work that has garnered over 50 citations and opened new avenues for risk stratification. His studies on neoadjuvant hormone therapy and salvage RARP further underscore his commitment to optimizing treatment for intermediate- and high-risk disease. With a portfolio of highly cited papers and a focus on both molecular mechanisms and surgical excellence, Hung stands out as a clinician-scientist dedicated to advancing personalized, patient-centered care in prostate oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10